Phase 1 Macular Degeneration Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are able to give written consent, understand what the study involves, and are willing to complete all required study procedures
• People aged 50 years or older
• People who have a specific type of eye condition called wet age-related macular degeneration (wet AMD) in one eye, with active abnormal blood vessel growth confirmed by specialised eye scans and photography
• People who have already received at least two prior injections into the eye (from treatments such as aflibercept, ranibizumab, bevacizumab, brolucizumab, or faricimab) and whose condition has not responded as well as hoped
• People whose vision in the study eye falls within a specific range — roughly between 20/40 and 20/400 on a standard eye chart
• People whose retinal scans show a certain level of fluid and retinal thickening in the study eye (specific measurement thresholds apply depending on the type of scan used — confirm with trial site)
• People who have not received any eye injection treatments for at least six weeks before the first study visit, and whose condition is stable enough to allow that gap, in the treating doctor's opinion

Who may not be able to join:

• People who have received steroid injections into or around the study eye within the past 90 days, or who are expected to need them during the study
• People with glaucoma that is not well controlled (for example, eye pressure above a certain level despite multiple glaucoma medications, significant vision field loss from glaucoma, or a history of glaucoma surgery) in either eye
• People who have another eye condition in the study eye — besides wet AMD — that could affect the study results (for example, active diabetic eye disease, certain types of inflammation, or significant short-sightedness)
• People whose wet AMD has reached an advanced stage with little or no chance of vision improvement, as judged by the treating doctor (for example, due to significant damage to the retina or a large bleed at the centre of vision)
• People who are expected to need eye surgery on the study eye during the trial
• People who had a specific type of laser eye procedure (YAG laser capsulotomy) within 30 days before the first study visit
• People who had any eye surgery, including lens removal or laser treatment, within 90 days before the first study visit
• People who currently have an infection in or around either eye
• People whose pupils cannot be dilated enough to allow clear retinal photography in the study eye
• People who have cloudiness or other changes inside the eye that would prevent clear imaging and scans of the study eye
• People with a history of herpes infection in or around the study eye
• People with a parasitic eye infection called toxoplasmosis (active or inactive) in either eye
• People with any form of eye cancer, including a type called choroidal melanoma, in either eye

Important: Always verify eligibility with the trial site directly before applying.